RESUMEN
Omphalitis is a rare infection in our countries. Streptoccus pyogenes is one of the most frequently encountered germs. Complications are rare but include septicemia and necrotizing fasciitis with a high mortality rate. The case reported in this article is that of an 11 days old infant with pyogenic streptococcal omphalitis who developed cellulitis of left food. An intravenous antibiotic treatment allowed complete resolution of the symptoms. The article is the opportunity to review of the risk factors of this affection, its complications and treatments.
L'omphalite est une infection rare dans nos pays. Le streptocoque pyogène est un des germes les plus fréquemment rencontrés. Les complications sont rares mais incluent les septicémies et la fasciite nécrosante avec un taux important de mortalité. Le cas rapporté dans cet article est celui d'un nourrisson de 11 jours présentant une omphalite à Streptocoque pyogène ayant développé une cellulite du pied gauche. Un traitement antibiotique intraveineux a permis une résolution complète des symptômes. Cet article est l'occasion d'une revue des facteurs de risques de cette affection, de ses complications et traitements.
Asunto(s)
Celulitis (Flemón)/diagnóstico , Pie/microbiología , Inflamación/diagnóstico , Infecciones Estreptocócicas/diagnóstico , Ombligo/microbiología , Celulitis (Flemón)/microbiología , Pie/patología , Humanos , Recién Nacido , Enfermedades del Recién Nacido/diagnóstico , Enfermedades del Recién Nacido/microbiología , Inflamación/microbiología , Masculino , Streptococcus pyogenes/aislamiento & purificación , Ombligo/patologíaRESUMEN
BACKGROUND: To investigate the safety and activity of cetuximab in the pre-operative treatment of squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Cetuximab was administered for 2 weeks before surgery to 33 treatment-naïve patients selected for primary surgical treatment. Tumour biopsies, 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography ((18)FDG-PET) and imaging were carried out at baseline and before surgery. The primary aim of the study was safety and the secondary aims included metabolical, radiological and pathological tumour response. Five untreated patients were included as controls. RESULTS: Cetuximab given 24 h before surgery was safe. Ninety percent of patients had (18)FDG-PET partial response (EORTC guideline) in the cetuximab group versus 0% in the control group. Delta maximal standardized uptake values (ΔSUVmax) were correlated with tumour cellularity on the surgical specimens (P < 0.0001). For patients with ΔSUVmax less than -25% or less than -50%, Ki67 was significantly decreased by cetuximab (P = 0.01 and 0.003). Cetuximab induced down-regulation of pEGFR (P = 0.0004) and pERK (P = 0.003). CONCLUSIONS: Short-course pre-operative administration of cetuximab is safe and shows a high rate of (18)FDG-PET response. (18)FDG-PET response was correlated with residual tumour cellularity suggesting that (18)FDG-PET deserves further investigation as a potential early marker of cetuximab activity in SCCHN.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma de Células Escamosas/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/efectos adversos , Antineoplásicos/efectos adversos , Carcinoma de Células Escamosas/diagnóstico por imagen , Carcinoma de Células Escamosas/cirugía , Cetuximab , Receptores ErbB/antagonistas & inhibidores , Fluorodesoxiglucosa F18 , Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Neoplasias de Cabeza y Cuello/cirugía , Humanos , Tomografía de Emisión de Positrones , Carcinoma de Células Escamosas de Cabeza y Cuello , Resultado del TratamientoRESUMEN
AIMS/HYPOTHESIS: Non-invasive imaging of the pancreatic beta cell mass (BCM) requires the identification of novel and specific beta cell biomarkers. We have developed a systems biology approach to the identification of promising beta cell markers. METHODS: We followed a functional genomics strategy based on massive parallel signal sequencing (MPSS) and microarray data obtained in human islets, purified primary rat beta cells, non-beta cells and INS-1E cells to identify promising beta cell markers. Candidate biomarkers were validated and screened using established human and macaque (Macacus cynomolgus) tissue microarrays. RESULTS: After a series of filtering steps, 12 beta cell-specific membrane proteins were identified. For four of the proteins we selected or produced antibodies targeting specifically the human proteins and their splice variants; all four candidates were confirmed as islet-specific in human pancreas. Two splice variants of FXYD domain containing ion transport regulator 2 (FXYD2), a regulating subunit of the Na(+)-K(+)-ATPase, were identified as preferentially present in human pancreatic islets. The presence of FXYD2gammaa was restricted to pancreatic islets and selectively detected in pancreatic beta cells. Analysis of human fetal pancreas samples showed the presence of FXYD2gammaa at an early stage (15 weeks). Histological examination of pancreatic sections from individuals with type 1 diabetes or sections from pancreases of streptozotocin-treated Macacus cynomolgus monkeys indicated a close correlation between loss of FXYD2gammaa and loss of insulin-positive cells. CONCLUSIONS/INTERPRETATION: We propose human FXYD2gammaa as a novel beta cell-specific biomarker.
Asunto(s)
Biomarcadores/metabolismo , Genómica/métodos , Células Secretoras de Insulina/metabolismo , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Animales , Western Blotting , Diabetes Mellitus Tipo 1/metabolismo , Humanos , Inmunohistoquímica , Técnicas In Vitro , Islotes Pancreáticos/metabolismo , Macaca/metabolismo , Análisis de Matrices TisularesRESUMEN
INTRODUCTION: Wegener's granulomatosis (WG) is a systemic necrotizing vasculitis associated with c-ANCA antibodies. The involvement of the central nervous system in WG is uncommon and usually caused by in situ vasculitis, intracranial granuloma formation or contiguous invasion from extracranial sites. CASE REPORT: Here, we report on a tumour-like expansion of a severe nasosinusal WG into the brain, which was confirmed by brain biopsy examination. CONCLUSION: The positivity of positron emission tomography in our observation supports the potential role of such functional imaging in the staging, as well as in the follow-up of WG.
Asunto(s)
Granulomatosis con Poliangitis/complicaciones , Biopsia , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Trastornos Cerebrovasculares/diagnóstico por imagen , Trastornos Cerebrovasculares/patología , Granulomatosis con Poliangitis/diagnóstico por imagen , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Senos Paranasales/diagnóstico por imagen , Senos Paranasales/patología , Tomografía Computarizada por Rayos XRESUMEN
Positron emission tomography (PET-scan) is a well-established imaging modality in oncology. Using FDG, PET has also a wide range of applications in head and neck tumors for diagnosis, staging, monitoring of response to therapy, and detection of relapse. After a short technical introduction, the current indications of PET-FDG in head and neck tumors are reviewed. Present and future developments of PET are twofold: the use of new tracers for protein synthesis, cellular proliferation or detection of hypoxia etc., and the introduction of metabolic imaging as a adjunct to CT and MRI to determine target-volumes in radiation treatment planning. However, it has to be emphasized that a thorough clinical validation of the methods used is mandatory before their implementation in routine practice.
Asunto(s)
Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Tomografía de Emisión de Positrones , Diagnóstico Diferencial , Fluorodesoxiglucosa F18 , Humanos , Recurrencia Local de Neoplasia/diagnóstico por imagen , Estadificación de Neoplasias/métodos , Pronóstico , RadiofármacosRESUMEN
After an introduction on the physical and biological basics of positron emission tomography, this paper reviews the current status of PET imaging using the glucose analogue FDG in colorectal cancer. The use of PET-FDG is reviewed for detection, initial staging, therapy monitoring and staging of disease relapse.
Asunto(s)
Neoplasias Colorrectales/diagnóstico por imagen , Tomografía de Emisión de Positrones , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/patología , Fluorodesoxiglucosa F18 , Glucosa/metabolismo , Humanos , Recurrencia Local de Neoplasia/diagnóstico , Estadificación de Neoplasias , RadiofármacosRESUMEN
AIM: To emphasise the pattern of lymphatic dissemination in the parapharyngeal space from thyroid cancer. PATIENTS AND METHOD: Among 696 patients treated for thyroid cancer between 1986 and 2001, parapharyngeal metastasis was diagnosed in three patients, previously treated for papillary thyroid carcinoma. RESULTS: All three patients have been treated by surgical resection through lateral cervical approach. Two of them were controlled regionally whereas the remaining one had a submucosal pharyngeal metastasis locally resected 27 months after parapharyngeal resection. CONCLUSIONS: Parapharyngeal metastasis is rare, but should be a recognized pattern of lymphatic dissemination from thyroid carcinoma to avoid unnecessary radioiodine and because surgical resection is efficacious with acceptable morbidity.
Asunto(s)
Carcinoma Papilar/secundario , Neoplasias de la Tiroides/patología , Humanos , Escisión del Ganglio Linfático , Ganglios Linfáticos/diagnóstico por imagen , Metástasis Linfática , Imagen por Resonancia Magnética , Faringe , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: To analyze the impact of positron emission tomography with fluorodeoxyglucose (FDG-PET) in the treatment of patients suspected of having head and neck cancer recurrence. STUDY DESIGN: Prospective and consecutive inclusion of 44 patients presenting with clinical symptoms suggestive of head and neck tumor recurrence. METHODS: FDG-PET was compared with combined computed tomography (CT) plus magnetic resonance imaging (MRI) procedures for the differential diagnosis between tumor recurrence and benign post-therapeutic changes. For FDG-PET, the potential additional value of semiquantitative indexes was studied. The impact on patient treatment (i.e., their ability to accurately select patients for panendoscopic exploration) was analyzed retrospectively for both CT+MRI and PET workups. RESULTS: The diagnostic accuracy was found higher for PET than for combined CT+MRI: sensitivity ranged from 96% to 73%, specificity from 61% to 50%, and accuracy from 81% to 64% for PET and CT+MRI, respectively. The accuracy of FDG-PET was the highest (94%) in patients included more than 12 weeks after the end of therapy. In 15 discordant cases, PET was correct in 11 and CT+MRI in 4. Patient selection for panendoscopic exploration and biopsy was correct in 79% and 50% of patients with FDG-PET and CT+MRI, respectively. Quantification of FDG uptake had no additional value over visual analysis alone, although we found that a SUVlbm (standardized uptake value corrected for lean body mass) threshold of 3 could be helpful in patients scanned less than 12 weeks after the end of therapy. CONCLUSION: FDG-PET has a major additional diagnostic value to CT+MRI for the evaluation of the symptomatic patient suspected of having head and neck cancer recurrence. PET could have a direct impact on management by correctly selecting patients in whom a panendoscopic exploration with biopsy is indicated.
Asunto(s)
Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Recurrencia Local de Neoplasia/diagnóstico por imagen , Tomografía Computarizada de Emisión , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Fluorodesoxiglucosa F18 , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/terapia , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/terapia , Valor Predictivo de las Pruebas , Estudios Prospectivos , Radiofármacos , Estudios Retrospectivos , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: To assess the effectiveness of positron emission tomography with radiolabeled [18F]-2-fluoro-deoxy-D-glucose (PET-FDG) imaging in mediastinal lymph node (LN) staging for non-small cell lung carcinoma (NSCLC) and to compare it to conventional clinical and surgical staging. METHODS: From June 1998 to February 2000, we enrolled 64 potentially resectable NSCLC patients in a prospective study of PET-FDG imaging of the mediastinum to assess LN involvement. Results of this technique were compared to conventional clinical and surgical staging. Diagnostic efficacy was determined by calculating sensitivity, specificity, overall accuracy, and positive and negative predictive values for each method. RESULTS: PET-FDG imaging correctly identified nodal stage (N0-N1 vs. N2) in 50 out of 61 patients (82%), overstaging occurred in eight patients (13%), and understaging in three patients (4.9%). The sensitivity, specificity, accuracy, and positive and negative predictive values for PET-FDG scan imaging were 67, 85, 82, 43, and 93.6%, respectively. Conventional staging correctly identified nodal stage (N0-N1 vs. N2) in 51 out of 62 patients (82%), overstaging occurred in five patients (8.1%), and understaging in six patients (9.7%). The sensitivity, specificity, accuracy, and positive and negative predictive values for conventional staging were 33, 90.6, 82, 37, and 89%, respectively. With regard to N2 disease, conventional staging showed a poor sensitivity (33%). Indeed, six out of 64 patients were understaged for mediastinal LN involvement. Even though the improvement was not statistically significant (McNemar P=0.08), the combined use of PET-FDG scan and computerized tomography (CT) scan allowed a two-fold increase in the sensitivity of our clinical preoperative staging. Moreover, relying on the PET-scan high negative predictive value might have contributed to a three-fold decrease in the number of required surgical staging procedures. CONCLUSIONS: Our study shows that the PET-FDG imaging strength lies in its very high negative predictive value and increased sensitivity. In this study, the overall accuracy of PET-FDG scan (82%) was lower than previously reported. Combined with chest CT-scan preoperatively, it may alleviate the need for surgical staging when PET-FDG studies of the mediastinum are negative. However, with a positive PET-FDG scan result, further diagnostic procedures should be pursued in order to avoid overstaging and allow better surgical patient selection.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Fluorodesoxiglucosa F18 , Neoplasias Pulmonares/diagnóstico por imagen , Radiofármacos , Tomografía Computarizada de Emisión , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Femenino , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Ganglios Linfáticos/diagnóstico por imagen , Metástasis Linfática , Masculino , Mediastinoscopía , Persona de Mediana Edad , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Estudios Prospectivos , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos XRESUMEN
In this study, we prospectively compared the sensitivity of PET and planar SPET (collimated gamma camera) 18F-FDG imaging in patients with lung and gastrointestinal tract cancer and analysed their respective impact on patient management. Twenty-eight patients with lung cancer and 14 with gastro-intestinal tract tumours were scanned on the same day with a PET and a collimated planar SPET gamma camera. The planar SPET procedure consisted of whole-body planar views and a tomographic acquisition centred over the torso or the abdomen, with the total imaging time within the same range as the whole-body PET procedure. The staging of lung cancer patients was accurate in 86% with PET and 64% with planar SPET. Planar SPET would have led to inappropriate therapeutic decisions in 8 of 28 patients, mainly due to undetected distant metastases. In patients with suspected gastrointestinal tract cancer, planar SPET identified 7 of 15 (47%) proven tumour sites, whereas PET identified 14 of 15 (93%). Our results suggest that collimated planar SPET cameras are not a substitute for dedicated PET scanners. The sensitivity for the detection of tumours is unacceptably low and can impair patient management. The use of multiple tomographic acquisitions could improve the sensitivity but would require a longer scanning time.
Asunto(s)
Fluorodesoxiglucosa F18 , Cámaras gamma , Neoplasias Gastrointestinales/diagnóstico por imagen , Neoplasias Pulmonares/diagnóstico por imagen , Radiofármacos , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada de Emisión , Neoplasias Colorrectales/diagnóstico por imagen , Neoplasias Colorrectales/patología , Radioisótopos de Flúor , Neoplasias Gastrointestinales/patología , Humanos , Neoplasias Pulmonares/patología , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/patología , Estudios Prospectivos , Sensibilidad y Especificidad , Tomografía Computarizada de Emisión/instrumentación , Tomografía Computarizada de Emisión de Fotón Único/instrumentaciónRESUMEN
Positron emission tomography (PET) is one of the most promising diagnostic procedures in oncology. Using the glucose analogue fluorodeoxyglucose, PET produces whole-body images and is highly sensitive for tumor diagnosis and staging. We review three particular clinical situations in which PET-FDG has proven not only its diagnostic accuracy, but also its impact on patient management, i.e., the staging of non-small cell lung cancer, diagnosis and staging of colo-rectal cancer and head and neck cancer recurrence. Image registration yields anatomo-metabolic images that could be used as additional information for the determination of radiation fields. Tracer and technical issues remain to be solved before PET can be routinely used for that purpose.
Asunto(s)
Neoplasias/diagnóstico por imagen , Tomografía Computarizada de Emisión , Neoplasias de los Bronquios/diagnóstico por imagen , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Carcinoma de Células Escamosas/diagnóstico por imagen , Neoplasias Colorrectales/diagnóstico por imagen , Fluorodesoxiglucosa F18/farmacocinética , Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Metástasis de la Neoplasia/diagnóstico por imagen , Recurrencia Local de Neoplasia/diagnóstico por imagen , Neoplasias/radioterapiaRESUMEN
Whole-body Tc-99m HDP scintigraphy was performed in a 25-year-old woman with known tuberous sclerosis. The scintigraphic pattern showed multiple foci of abnormal activity over the hands, phalanges, feet, tibias, fibulas, ulnas, and radii, where radiographs showed periosteal apposition, irregular cortical thickening, and cystlike lesions on the phalanges. The spine, pelvis, and ribs showed heterogeneous tracer uptake where radiographs showed patchy areas of increased bone density. This radiographic pattern is characteristic of osseous tuberous sclerosis. Although previous reports suggested the opposite conclusion, this observation indicates that an abnormal result of bone scintiscan can be observed in osseous tuberous sclerosis.
Asunto(s)
Huesos/diagnóstico por imagen , Radiofármacos , Medronato de Tecnecio Tc 99m/análogos & derivados , Esclerosis Tuberosa/diagnóstico por imagen , Adulto , Femenino , Humanos , CintigrafíaRESUMEN
Somatostatin receptor imaging with In-111 pentetreotide has been validated for the diagnosis and staging of chest tumors with neuroendocrine differentiation such as bronchial carcinoid and small cell lung cancer. In-111 pentetreotide uptake is not specific for neuroendocrine tumors because somatostatin receptors are also expressed by white blood cells, leading to the in vivo visualization sites of infection sites or active inflammation. Pleural plaques may be due to asbestos exposure or tuberculosis. Presented here are three cases of In-111 pentetreotide uptake in pleural plaques. This uptake by benign lesions may be misleading in the diagnostic work-up of patients with lung tumors.
Asunto(s)
Radioisótopos de Indio , Enfermedades Pleurales/diagnóstico por imagen , Somatostatina/análogos & derivados , Anciano , Amianto , Neoplasias de los Bronquios/diagnóstico por imagen , Tumor Carcinoide/diagnóstico por imagen , Carcinoma de Células Pequeñas/diagnóstico por imagen , Diagnóstico Diferencial , Fibrosis , Humanos , Radioisótopos de Indio/farmacocinética , Leucocitos/metabolismo , Neoplasias Pulmonares/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/diagnóstico por imagen , Pleura/diagnóstico por imagen , Pleura/patología , Nódulo Pulmonar Solitario/diagnóstico por imagen , Somatostatina/farmacocinética , Tomografía Computarizada de Emisión de Fotón Único , Tuberculosis Pleural/diagnóstico por imagenAsunto(s)
Carcinoma Neuroendocrino/diagnóstico por imagen , Neoplasias Hepáticas/diagnóstico por imagen , Somatostatina/análogos & derivados , Tomografía Computarizada de Emisión/métodos , Carcinoma Neuroendocrino/secundario , Fluorodesoxiglucosa F18 , Humanos , Radioisótopos de Indio , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/secundario , Metástasis de la Neoplasia , Estadificación de Neoplasias , RadiofármacosRESUMEN
BACKGROUND AND STUDY AIMS: Transoesophageal endosonography with fine needle aspiration (EUS-FNA) and 2-deoxy-2-[fluorine-18]fluoro-D-glucose positron emission tomography (FDG-PET) are now standard diagnostic procedures of the mediastinum. Our aim was to compare their value in the assessment of enlarged mediastinal lymph nodes detected by computed tomography. PATIENTS AND METHODS: Forty consecutive patients with a suspicion of cancer or a history of pulmonary, digestive, urogenital or mammary neoplasia and presenting with supracentimetric lymph nodes on computed tomography underwent whole body FDG-PET and EUS-FNA. Final diagnosis of malignancy was obtained by cytology, surgery or long-term follow-up. RESULTS: EUS-FNA showed a sensitivity, specificity and accuracy for detection of malignancy of 793, 100 and 85%, respectively. The biopsy material was adequate for cytological examination in 37 patients. Sensitivity, specificity and accuracy of PET were 100, 54.5 and 87.5%, respectively. FDG-PET correctly diagnosed the primary site in 27 patients, and showed additional unknown extrathoracic metastatic sites in 15 patients. The five false positive results observed with FDG-PET consisted in a final diagnosis of sarcoidosis, tuberculosis, anthracosilicosis and reactive lymph nodes, respectively. The association of FDG-PET and EUS-FNA avoided more invasive procedures (mediastinoscopies or staging surgery) in 34 patients. CONCLUSIONS: EUS-FNA and FDG-PET are complementary diagnostic procedures combining the high sensitivity of FDG-PET and the high specificity of EUS-FNA to accurately diagnose malignancy in enlarged mediastinal lymph nodes identified by CTscan. The combination of the two procedures in selected cases with pulmonary cancer or extra-thoracic tumours avoided more invasive diagnostic and surgical procedures.
Asunto(s)
Biopsia con Aguja Fina/métodos , Endosonografía/métodos , Ganglios Linfáticos/patología , Enfermedades Linfáticas/diagnóstico , Adulto , Anciano , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Humanos , Ganglios Linfáticos/diagnóstico por imagen , Metástasis Linfática/diagnóstico , Masculino , Mediastino , Persona de Mediana Edad , Estudios Prospectivos , Reproducibilidad de los Resultados , Factores de TiempoRESUMEN
PURPOSE: The aim of this study was to assess the pharmacokinetics, biodistribution and metabolism of [(18)F]EF3, a labelled 2-nitroimidazole hypoxia marker, in ten patients with head and neck cancer. METHODS: [(18)F]EF3 was administered intravenously (group 1, n=5, mean dose+/-SD: 324+/-108 MBq; group 2, n=5, mean dose+/-SD: 1,134+/-138 MBq) to patients (nine male, one female). Blood and urine samples and whole-body PET scans were obtained from 20 s to 4-6 h. Radioactivity was determined in several regions of interest. RESULTS: No serious adverse event was reported. [(18)F]EF3 concentration in blood exhibited a bi-exponential decline. [(18)F]EF3 was mainly eliminated in the urine. By 7 h 40 min after injection, 53+/-14% of the injected dose was collected in the urine. There was no significant difference between the low- and high-dose groups. A progressive accumulation occurred also in the colon, indicating a hepatobiliary excretion. Except in organs involved in the elimination of [(18)F]EF3, the tumour-to-organ ratio remained close to or below unity in muscle, lungs, heart and brain at various times after injection. In one patient, tumour hypoxia was observed with a tumour-to-blood ratio ranging from 1.4 to 1.9. Last, [(18)F]EF3 remained very stable after injection, with percentage of native tracer above 87% in the serum and 84% in the urine. CONCLUSION: Administration of [(18)F]EF3 in head and neck cancer patients is feasible and safe. Uptake and retention in tumour was observed, indicating the presence of hypoxia.
Asunto(s)
Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Hipoxia/diagnóstico por imagen , Nitroimidazoles/farmacocinética , Adulto , Anciano , Carcinoma de Células Escamosas/diagnóstico por imagen , Femenino , Humanos , Neoplasias Laríngeas/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Neoplasias Faríngeas/diagnóstico por imagen , Tomografía de Emisión de Positrones , Radiofármacos/farmacocinética , Distribución TisularRESUMEN
Purpose: To analyze the efficacy and impact on management of PET-FDG in patients with metastases from unknown primary tumor.Procedures: Retrospective analysis of 24 patients referred to the PET center for metastasis of unknown primary after a negative imaging workup. PET results were validated by means of oriented imaging, follow-up or biopsy when ethically justified.Results: PET identified the primary tumor in 13/24 (54%) of patients: breast (n = 1), lung (n = 9), colon (n = 1), stomach (n = 1) and mouth (n = 1). The false positive rate of PET was 21% (5/24). PET was shown to affect the management of 10/24 patients (42%).Conclusion: Whole body PET-FDG was more effective than conventional imaging methods in detecting unknown primary tumors. PET altered patient management in 42% of cases. PET should be performed prior to other investigations in such patients and could avoid unnecessary and often unfruitful diagnostic procedures.
RESUMEN
We report the case of a MEN 2a patient with a history of medullary thyroid cancer (MTC) treated by total thyroidectomy, who presented an increasing calcitonin level, suggesting tumor recurrence. Conventional radiographic and radionuclide imaging failed to localize the responsible lesions. A planar and tomographic (SPECT) [99mTc]MIBI scan, performed in order to investigate a recent hyperparathyroidism localized a parathyroid adenoma and revealed an abnormal uptake in the left lateral neck region, corresponding to apparently banal lymph nodes on MRI. This abnormal uptake was also observed on a [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) study and was proven to be an uptake in MTC lymph nodes metastases as confirmed by histopathologic analysis. We conclude that, using an adequate acquisition protocol (i.e. SPECT), [99mTc]MIBI scan is potentially able to localize both parathyroid adenoma and recurrent MTC at one and the same time, particularly in case of non-diagnostic conventional imaging techniques. In this setting, the potential usefulness of FDG-PET is also discussed.
Asunto(s)
Carcinoma Medular/diagnóstico por imagen , Hiperparatiroidismo/diagnóstico por imagen , Neoplasia Endocrina Múltiple Tipo 2a/diagnóstico por imagen , Recurrencia Local de Neoplasia/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico por imagen , Adulto , Carcinoma Medular/complicaciones , Carcinoma Medular/patología , Carcinoma Medular/cirugía , Fluorodesoxiglucosa F18 , Estudios de Seguimiento , Humanos , Hiperparatiroidismo/complicaciones , Hiperparatiroidismo/patología , Masculino , Neoplasia Endocrina Múltiple Tipo 2a/complicaciones , Neoplasia Endocrina Múltiple Tipo 2a/patología , Recurrencia Local de Neoplasia/complicaciones , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/cirugía , Radioisótopos , Cintigrafía , Sensibilidad y Especificidad , Tecnecio Tc 99m Sestamibi , Neoplasias de la Tiroides/complicaciones , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/cirugíaRESUMEN
Concurrent radionecrosis within the spinal cord and the bone marrow at the same thoracic level was observed 8 years after localized therapeutic irradiation in a patient who had undergone repeated cycles of radiotherapy, glucocorticoid treatment, and chemotherapy for a non-Hodgkin's lymphoma. Mechanisms combining radiotoxic potentialization by glucocorticoids/alkylating agents and delayed radiation-induced vasculitis involving the common arterial pathways to the spinal cord and to the vertebrae were speculated to have acted in a synergistic way.